Mark Leong – Executive Chairman – Osteopore (ASX:OSX) is a Singapore-headquartered corporation poised to be a leading medical device company in the region. It is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.
Copyright 2023 – Finance News Network
Source: Finance News Network
28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
Read More10 May 2024 - Exploring tin's revival: Elementos CEO & MD Joe David discusses market trends and project developments.
Read More05 Feb 2025 - CEO Andrew Terry discusses long-range wi-fi, semiconductor challenges, and the future of IoT connectivity.
Read More27 Jul 2022 - TerraCom Limited (ASX:TER) Managing Director Danny McCarthy discusses highlights of the company's June quarter results, the recent rains in Queensland, the mine life and run rate of the company's key asset Blair Athol and the outlook for coal.
Read More16 Aug 2023 - Steven Yatomi Clarke - CEO and Managing Director - Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Read More17 Sep 2019 - Tinybeans Limited (ASX:TNY) Founder & CEO, Eddie Geller discusses the company's FY19 results, growth users to its platform, new services and strategy.
Read More24 Nov 2020 - Imdex (ASX:IMD) Limited CEO Paul House discusses the company's financial update, outlook and strategy, and provides an introduction to its technology, which improves the productivity of drill rigs, data collection and analysis.
Read More08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
Read More09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
Read More20 Jul 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO Giles Bourne gives an update on the commissioning of the BLG 500 at Silverwater, strategic alliances and product roadmap.
Read More
